每经头条（nbdtoutiao）——超10万人挤爆服务器，围观8家房企抢"马场"：9小时竞价243轮，236亿元 成交！广州楼面价新地王诞生：8.5万元/㎡ （记者 张明双） 每经AI快讯，圣湘生物2月26日晚间发布公告称，圣湘生物科技股份有限公司控股子公司中山圣湘海济 生物医药有限公司于近日收到国家药品监督管理局签发的《药品补充申请批准通知书》，其产品人生长 激素注射液拟新增用于特发性矮身材（ISS）的适应症补充申请已获得国家药监局的临床试验批准。 ...

圣湘生物科技股份有限公司 关于自愿披露控股子公司产品新增适应症获 得临床试验批准的公告 证券代码：688289 证券简称：圣湘生物 公告编号：2026-002 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 圣湘生物科技股份有限公司（以下简称"公司"）控股子公司中山圣湘海济 生物医药有限公司（以下简称"圣湘海济"）于近日收到国家药品监督管理局（以 下简称"国家药监局"）签发的《药品补充申请批准通知书》，其产品人生长激 素注射液（商品名称：海之元®）拟新增用于特发性矮身材（ISS）的适应症补充 申请已获得国家药监局的临床试验批准。现将相关情况公告如下： 一、基本情况 药品名称：人生长激素注射液 商品名称：海之元® 注册分类：治疗用生物制品 受理号：CYSB2500314 申请人：中山圣湘海济生物医药有限公司 申请内容：申请增加"特发性矮身材（ISS）"适应症的临床试验 剂型：注射剂 规格：30IU/10mg/3ml/瓶 通知书编号：2026B01038 药品批准文号：国药准字 S20230064 上市许可持有人：中山圣湘海济 ...

圣湘生物公告，控股子公司中山圣湘海济生物医药有限公司收到国家药监局签发的《药品补充申请批准 通知书》，其产品人生长激素注射液（商品名称：海之元 ）拟新增用于特发性矮身材（ISS）的适应症 补充申请已获得国家药监局的临床试验批准。人生长激素注射液（海之元 ）是基于圣湘海济注射用人 生长激素开发的水针剂型，已于2023年11月7日获批上市，用于因内源性生长激素缺乏所引起的儿童生 长缓慢、因Noonan综合征所引起的儿童身材矮小。 ...

Core Viewpoint - The diagnostic reagent industry in China is experiencing fluctuations in market size due to the impact of COVID-19, with a projected recovery and growth expected by 2025, reaching a market size of 140 billion yuan, an 8% increase year-on-year [6][7]. Industry Overview - Diagnostic reagents are essential tools in medicine and biology for detecting diseases, infections, and other medical conditions through interactions with biological samples [4][6]. - The market is primarily dominated by in vitro diagnostic reagents, while in vivo diagnostics remain relatively small [6]. Market Size and Trends - The market for in vitro diagnostic reagents in China has shown an upward trend since 2015, with rapid growth from 2020 to 2022 due to the pandemic, but a 14% decline in 2023 due to reduced demand for COVID-19 diagnostic reagents [6][7]. - The market is expected to recover in 2024, with projections indicating a market size of 140 billion yuan by 2025, reflecting an 8% year-on-year growth [6][7]. Competitive Landscape - The diagnostic reagent market includes both domestic companies like Mindray Medical, Antu Bio, and Wanfu Bio, and international firms such as Roche Diagnostics and Abbott, all competing for market share [8]. - Domestic companies are noted for their strong R&D capabilities and significant market presence [8]. Industry Development Stages - The diagnostic reagent industry in China has progressed through four stages: nascent, initial, extensive development, and rapid growth, with significant advancements in technology and regulatory improvements since the 21st century [5]. Industry Chain - The industry chain consists of upstream raw materials (diagnostic enzymes, antigens, antibodies, etc.), the midstream diagnostic reagent production, and downstream applications in medical institutions and third-party diagnostic organizations [6]. Market Segmentation - The in vitro diagnostic reagent market is segmented, with immunodiagnostic reagents holding a 32% market share, followed by molecular diagnostic reagents at 19%, and biochemical diagnostic reagents at 18% [7]. Future Trends - The industry is expected to focus on high-end product upgrades, with companies increasing R&D investments to enhance product value amidst price pressures from centralized procurement [9]. - There is a trend towards market penetration in lower-tier cities and global expansion, with domestic products entering emerging markets in Southeast Asia and Africa [10]. - The industry is evolving towards a model centered on clinical value and personalized medicine, integrating diagnostic solutions with treatment recommendations [11].

证券代码：688289 证券简称：圣湘生物 公告编号：2026-001 圣湘生物科技股份有限公司 关于与专业机构共同投资设立基金暨关联交 易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 投资标的名称 | 湖南金芙蓉圣湘生物股权投资基金合伙企业（有限合伙） | | | | | --- | --- | --- | --- | --- | | 投资金额（万元） | 37,000 | | | | | 投资进展阶段 | 完成 | 终止 | 交易要素变更 | 进展 | | | 募集失败 | | | | | | 未能完成备案登记 | | | | | | 提前终止 | | | | | | 发生重大变更 | | | | | 特别风险提示 | 其他：由于投资基金属于长期股权投资，具有投资周 | | | | | | 期长，流动性较低的特点，本次投资将面临较长的投资 | | | | | | 回收期，且存在因受宏观政策、经济环境、行业周期、 | | | | | | 投资标的经营管理、交易方案等多种 ...

以上内容基于公开资料整理，不构成投资建议。 股票近期走势 截至2026年2月11日收盘，圣湘生物股价报19.81元，当日下跌0.95%，近5日累计下跌0.90%；2月10日主 力资金净流出622.99万元，占成交额8.22%。最新资金流向显示，2月11日主力资金净流出约2435万元， 散户资金净流入，换手率0.74%。同期，医疗器械板块整体下跌0.48%，大盘指数表现分化。 经济观察网2026年2月11日，圣湘生物新增一起对外投资，被投资公司为湖南金芙蓉圣湘生物股权投资 基金合伙企业(有限合伙)，出资额8.2亿元，投资占比45.12%，从事股权投资等资本市场服务。同日，公 司通过董秘问答重申，自2021年以来已实施3轮回购方案，累计回购资金5.8亿余元，并于2024年及2025 年注销股份907万余股，以提升每股收益和股东回报。此外，公司于2026年2月6日回应国际业务进展， 强调在欧洲市场通过"平台一体化"和本地化子公司模式拓展业务。 ...

企查查APP显示，近日，湖南金芙蓉圣湘生物股权投资基金合伙企业（有限合伙）成立，出资额8.2亿元，经营范围包含：以私募基金从事股权投资、投资 管理、资产管理等活动。企查查股权穿透显示，该企业由圣湘生物（688289）等共同出资。 | 序号 | | 合伙人名称 | 出资比例 ⇒ | | --- | --- | --- | --- | | 1 | + | 圣湘生物科技股份有限公司 | 45.1220% | | | | 圣湘生物 (688289.SH) ญ | | | 2 | + | 湖南省金美蓉产业引导基金合伙企业(有限合伙) | 26.8293% | | | | 部 国有企业 私募基金 | | | 3 | + | 湖南湘江新区引导四号股权投资合伙企业（有限合伙） 락 물 | 18.2927% | | | | 四号 国有企业 私募基金 | | | ব | | 长沙市科技成果转化天使投资引导基金合伙企业(有限合伙) | 8.5366% | | | | 国有企业 私募基金 | | 长沙圣维荣泉创业投资有限公司 圣维 5 + 执行事务合伙人 私募基金管理人 荣泉 1.2195% | IL a c Qcc.com 全国企 ...

Investment Rating - The report maintains an "Overweight" rating for the in vitro diagnostics (IVD) industry [7]. Core Views - The recent policy from the National Healthcare Security Administration aims to transform the role of healthcare insurance from a payer to an innovator, significantly impacting the IVD industry by promoting solutions that integrate "testing + AI + services" [5][51]. - The domestic IVD industry is currently in a bottoming phase, with a strong focus on the growth potential of immunodiagnostics, particularly in chemiluminescence and molecular diagnostics such as PCR [5][51]. - The report highlights that the biochemical diagnostics sector in China has largely completed its localization process, reducing reliance on foreign technologies [5]. Summary by Sections Industry Performance - The pharmaceutical and biological sector rose by 0.14%, ranking 15th among 31 primary industries, while the IVD sector fell by 1.28% [2][10]. - The IVD sector's current PE (ttm) is 39.37X, with a PB (lf) of 1.80X, showing a slight decrease from the previous week [4][31]. Company Performance - Notable performers in the medical services sector include SAIKOSHI (+14.5%), Ruiang Gene (+3.1%), and Rendu Bio (+2.6%), while underperformers include Cap Bio (-6.8%) and Hotgen Bio (-6.4%) [3][26]. - The report suggests focusing on companies like YHLO Biotech and Shengxiang Bio in the immunodiagnostics and molecular diagnostics fields due to their growth potential [5][51]. Market Trends - The report indicates that the IVD industry is experiencing a shift towards integrating new technologies and payment methods, driven by recent policy changes [5][51]. - The overall IVD market is expected to continue its steady growth, with significant opportunities arising from the integration of AI and innovative products [5][51].

Core Viewpoint - The company is transforming its international business model from traditional product export to an integrated platform approach, focusing on building a global health ecosystem through collaboration with local healthcare systems and public health institutions [2] Group 1: International Market Strategy - The company aims to upgrade its international business from "single-point cooperation" to "ecological collaboration" by leveraging a "platform integration and diagnostic integration" strategy [2] - In response to the high standards and specialization demands of the European market, the company is developing a tailored ecosystem model that includes "high-end diagnostics, customized services, and partner collaboration" [2] Group 2: Sales and Localization - The company's sales strategy primarily relies on distribution, supplemented by direct sales, utilizing local subsidiaries in countries like France and the UK to enhance market penetration [2] - The company is focused on building localized teams, regional service networks, and implementing benchmark projects to strengthen its international ecological construction [2]

证券日报网讯 2月6日，圣湘生物在互动平台回答投资者提问时表示，公司以"平台一体化、诊疗一体 化"为核心引擎，深度链接全球产业链伙伴、当地医疗体系与公共卫生机构，构建起"技术共享-能力共 建-价值共生"的全球健康生态，推动国际业务从"单点合作"向"生态协同"升级。2025年，公司海外深耕 取得长足发展，业务版图稳步拓展，全球资源配置效率有效提升。公司于今年1月对德国inno- trainDiagnostikGmbH的收购，是公司国际化战略的又一项重要战略布局，进一步强化了公司在高端血液 分子诊断领域的全球布局，为构建全链条诊疗一体化生态注入关键动能。公司高度重视资产减值与商誉 评估，年度报告财务数据均严格遵循会计准则并经过审计，具体内容可详见公司披露的财务报表及其附 注。 （文章来源：证券日报） ...